Health

argenx to Present at TD Cowen 46th Annual Healthcare Conference

February 23, 2026 01:00 ET  | Source: argenx SE February 23, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX),…

1 month ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

February 22, 2026 16:00 ET  | Source: Dyne Therapeutics, Inc. - Late-breaking poster to feature new positive cardiopulmonary function results…

1 month ago

Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics Joint Replacement Institute outpatient center

PALO ALTO, Calif. and MULGRAVE, Australia, Feb. 22, 2026 (GLOBE NEWSWIRE) -- Gyder Surgical, a MedTech company specializing in intuitive, non-invasive…

1 month ago

Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones

Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions,…

2 months ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 months ago

U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…

2 months ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics…

2 months ago

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed…

2 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage…

2 months ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease…

2 months ago